Larimar Therapeutics (LRMR) Cash from Operations: 2013-2020
Historic Cash from Operations for Larimar Therapeutics (LRMR) over the last 7 years, with Dec 2020 value amounting to -$9.9 million.
- Larimar Therapeutics' Cash from Operations fell 24.60% to -$9.9 million in Q4 2020 from the same period last year, while for Dec 2020 it was -$42.2 million, marking a year-over-year decrease of 85.91%. This contributed to the annual value of -$70.8 million for FY2024, which is 111.34% down from last year.
- Larimar Therapeutics' Cash from Operations amounted to -$9.9 million in Q4 2020, which was up 12.16% from -$11.2 million recorded in Q3 2020.
- Larimar Therapeutics' Cash from Operations' 5-year high stood at $3.5 million during Q2 2019, with a 5-year trough of -$17.8 million in Q1 2016.
- In the last 3 years, Larimar Therapeutics' Cash from Operations had a median value of -$11.5 million in 2018 and averaged -$9.7 million.
- Its Cash from Operations has fluctuated over the past 5 years, first surged by 126.34% in 2019, then slumped by 447.95% in 2020.
- Quarterly analysis of 5 years shows Larimar Therapeutics' Cash from Operations stood at -$8.7 million in 2016, then fell by 13.50% to -$9.8 million in 2017, then declined by 20.31% to -$11.8 million in 2018, then skyrocketed by 33.15% to -$7.9 million in 2019, then fell by 24.60% to -$9.9 million in 2020.
- Its Cash from Operations was -$9.9 million in Q4 2020, compared to -$11.2 million in Q3 2020 and -$12.2 million in Q2 2020.